Which Patients With H. pylori Are at Increased Risk of Gastric Cancer?

Answer in brief: Gastric cancer risk is highest when H. pylori infection occurs in a patient who already has gastric atrophy or intestinal metaplasia, a first-degree family history of gastric cancer, origin from a high-incidence region, prior gastric neoplasia, autoimmune gastritis, or certain hereditary cancer syndromes. Eradication is recommended, but some patients remain at enough residual risk to justify endoscopic staging or surveillance.

H. pylori is a carcinogenic exposure, but host risk is heterogeneous

Chronic H. pylori infection can progress through gastritis, gland loss, intestinal metaplasia, dysplasia and adenocarcinoma. Not every infected person follows that pathway. Cancer prevention therefore requires both eradication and recognition of patients in whom substantial mucosal damage has already developed.

Look for premalignant mucosal disease

Atrophic gastritis and gastric intestinal metaplasia are the most important endoscopic/pathologic clues. Risk increases when disease is extensive, involves the corpus, is histologically severe, or shows incomplete-type intestinal metaplasia. Dysplasia is a higher-risk state requiring specialist management.

Family history and geography matter

A first-degree relative with gastric cancer raises concern. So does birth in or long-term residence in a region with high gastric-cancer incidence. These factors should lower the threshold for high-quality endoscopy and systematic gastric biopsies when clinically appropriate.

Prior gastric neoplasia changes the baseline

Patients who have undergone endoscopic or surgical treatment for early gastric neoplasia remain at risk of metachronous lesions. H. pylori eradication is important but does not substitute for appropriate surveillance.

The practical prevention sequence

Identify infection, treat with an evidence-based regimen, confirm eradication, stage the stomach when risk factors justify endoscopy, and then decide whether residual risk warrants surveillance. This is a more useful model than treating infection and assuming risk has returned to zero.

What trainees should remember

Eradicate H. pylori in everyone who is treated, but think beyond infection status. The patients who most need risk stratification are those with premalignant mucosa, family history, high-incidence ancestry/geography or previous gastric neoplasia.

Frequently asked questions

Does eradication eliminate gastric cancer risk?

No. It lowers risk, especially when performed before advanced mucosal damage develops, but residual risk persists in patients with atrophy, intestinal metaplasia or prior neoplasia.

Should every H. pylori patient undergo endoscopy?

No. Endoscopy is targeted according to symptoms, age, alarm features and gastric-cancer risk rather than performed routinely in every infected patient.

References and further reading

1. Thomson ABR. Best Practice Guidelines in Gastroenterology Disorders. CAPstone Academic Publishers; 2024.

2. Thomson ABR. Practice Review in Gastroenterology. CAPstone Academic Publishers; 2014.

3. Chey WD, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2024.

4. Morgan DR, et al. ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions. Am J Gastroenterol. 2025.